LABELS · ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

OGIVRI

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-26
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. Evaluate left ventricular function in all patients prior to and during treatment with Ogivri. Discontinue Ogivri treatment in patients receiving adjuvant therapy and withhold Ogivri in patients with metastatic disease for clinically significant decrease in left ventricular function [see Dosage and Administration (2.5) and Warnings and Precautions (5.1) ] . Infusion Reactions; Pulmonary Toxicity Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration of trastuzumab products. Interrupt Ogivri infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue Ogivri for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome [see Warnings and Precautions (5.2 , 5.4 )] . Embryo-Fetal Toxicity Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1 , 8.3 )] . WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Ogivri for cardiomyopathy. ( 2.5 , 5.1 ) Infusion Reactions, Pulmonary Toxicity: Discontinue Ogivri for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.2 , 5.4 ) Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception. ( 5.3 , 8.1 , 8.3 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] .

Full extracted label fields

application numbers

BLA761074

boxed warning exact

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. Evaluate left ventricular function in all patients prior to and during treatment with Ogivri. Discontinue Ogivri treatment in patients receiving adjuvant therapy and withhold Ogivri in patients with metastatic disease for clinically significant decrease in left ventricular function [see Dosage and Administration (2.5) and Warnings and Precautions (5.1) ] . Infusion Reactions; Pulmonary Toxicity Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration of trastuzumab products. Interrupt Ogivri infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue Ogivri for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome [see Warnings and Precautions (5.2 , 5.4 )] . Embryo-Fetal Toxicity Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1 , 8.3 )] . WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Ogivri for cardiomyopathy. ( 2.5 , 5.1 ) Infusion Reactions, Pulmonary Toxicity: Discontinue Ogivri for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.2 , 5.4 ) Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception. ( 5.3 , 8.1 , 8.3 )

brand names

OGIVRI

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6465b44-a6dd-f99c-d009-6851cf05169c

generic names

TRASTUZUMAB-DKST

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

indications and usage exact

1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Biocon Biologics Inc.

matched search terms

cancer

package ndcs

83257-004-12
83257-003-11
83257-002-11
83257-003-01
83257-001-11

product ndcs

83257-001
83257-004
83257-003

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Dosage and Administration, Evaluation and Testing Before Initiating Ogivri ( 2.1 ) 11/2024

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

2179753
2179758
2179760
2179763

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761074

brand names

OGIVRI

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 341
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic fo
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 0

current approval status

not_reconciled

duplicate text group

dup-4447ca69b9a8bcd08c17

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-8abf5bea3469fdd0d639

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

end: 74
end exclusive: true
exact text: is a HER2/neu receptor antagonist indicated
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 31

qualifier mentions

context exact
USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.
kind
age
polarity
not_inferred
span
end
84
end exclusive
true
exact text
adults
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
78
context exact
1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer
kind
biomarker
polarity
not_inferred
span
end
80
end exclusive
true
exact text
HER2/neu receptor antagonist indicated in ad
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
36
context exact
ceptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.
kind
biomarker
polarity
not_inferred
span
end
140
end exclusive
true
exact text
HER2-overexpressing breast cancer
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
107

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 141
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · unclassified context

application numbers

BLA761074

brand names

OGIVRI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 456
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatmen
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 0

current approval status

not_reconciled

duplicate text group

dup-b5f3b03427890f624764

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-d287d447ad6d555e42fc

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

Source null

qualifier mentions

context exact
( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
kind
biomarker
polarity
not_inferred
span
end
217
end exclusive
true
exact text
HER2-overexpressing metastatic gastric or ga
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
173
context exact
( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
kind
stage_or_setting
polarity
not_inferred
span
end
238
end exclusive
true
exact text
metastatic gastric or gastroesophageal juncti
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
193

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 256
end exclusive: true
exact text: ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 142

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

BLA761074

brand names

OGIVRI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 577
end exclusive: true
exact text: agonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studi
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 57

current approval status

not_reconciled

duplicate text group

dup-ad83e05ed30aa7f359c7

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-2ec94bf8fa1eaa47617a

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 377
end exclusive: true
exact text: ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ).
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 257

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761074

brand names

OGIVRI

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1049
end exclusive: true
exact text: overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated in adults:
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 178

current approval status

not_reconciled

duplicate text group

dup-0f94c5804779bc8ff6d8

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-1c4957abe8bd628cd66c

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

end: 424
end exclusive: true
exact text: is indicated
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 412

qualifier mentions

context exact
1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive
kind
age
polarity
not_inferred
span
end
434
end exclusive
true
exact text
adults
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
428
context exact
cer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Cl
kind
biomarker
polarity
not_inferred
span
end
505
end exclusive
true
exact text
HER2 overexpressing node positive or node ne
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
461
context exact
1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node
kind
stage_or_setting
polarity
not_inferred
span
end
425
end exclusive
true
exact text
Adjuvant Breast Cancer Ogivri is indicated
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
382
context exact
.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one hi
kind
stage_or_setting
polarity
not_inferred
span
end
482
end exclusive
true
exact text
adjuvant treatment of HER2 overexpressing n
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
439
context exact
part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy.
kind
regimen
polarity
not_inferred
span
end
848
end exclusive
true
exact text
as a single agent following multi-modality anthracycline based therapy
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
778

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 849
end exclusive: true
exact text: 1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy.
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 378

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

BLA761074

brand names

OGIVRI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1189
end exclusive: true
exact text: doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 650

current approval status

not_reconciled

duplicate text group

dup-7cfdbb696950f9e4cd35

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-06ef9d564a8410c12655

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 989
end exclusive: true
exact text: Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ].
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 850

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

BLA761074

brand names

OGIVRI

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1510
end exclusive: true
exact text: agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated in adults
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 790

current approval status

not_reconciled

duplicate text group

dup-b303a39fb1564f5c16c2

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-a12a42e13dd6767bc10d

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

end: 1038
end exclusive: true
exact text: is indicated
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1026

qualifier mentions

context exact
1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of
kind
age
polarity
not_inferred
span
end
1048
end exclusive
true
exact text
adults
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1042
context exact
1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line t
kind
biomarker
polarity
not_inferred
span
end
1037
end exclusive
true
exact text
Metastatic Breast Cancer Ogivri is indicate
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
994
context exact
In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing brea
kind
biomarker
polarity
not_inferred
span
end
1153
end exclusive
true
exact text
HER2-overexpressing metastatic breast cancer
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1109
context exact
metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for me
kind
biomarker
polarity
not_inferred
span
end
1233
end exclusive
true
exact text
HER2-overexpressing breast cancer in patient
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1189
context exact
nts who have received one or more chemotherapy regimens for metastatic disease.
kind
biomarker
polarity
not_inferred
span
end
1309
end exclusive
true
exact text
metastatic disease
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1291
context exact
1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line tre
kind
stage_or_setting
polarity
not_inferred
span
end
1039
end exclusive
true
exact text
Metastatic Breast Cancer Ogivri is indicated
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
994
context exact
paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients
kind
stage_or_setting
polarity
not_inferred
span
end
1174
end exclusive
true
exact text
metastatic breast cancer As a single agent fo
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1129
context exact
nts who have received one or more chemotherapy regimens for metastatic disease.
kind
stage_or_setting
polarity
not_inferred
span
end
1309
end exclusive
true
exact text
metastatic disease
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1291
context exact
is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1255
end exclusive
true
exact text
first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received on
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1085
context exact
1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens fo
kind
regimen
polarity
not_inferred
span
end
1229
end exclusive
true
exact text
In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in pat
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1050

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1310
end exclusive: true
exact text: 1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 990

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · unclassified context

application numbers

BLA761074

brand names

OGIVRI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1650
end exclusive: true
exact text: R2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastri
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1111

current approval status

not_reconciled

duplicate text group

dup-7cfdbb696950f9e4cd35

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-0e0b587bd77ce413cf67

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1450
end exclusive: true
exact text: Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ].
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1311

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761074

brand names

OGIVRI

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1898
end exclusive: true
exact text: d one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] .
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1251

current approval status

not_reconciled

duplicate text group

dup-cadda3a098d41b5b4b7f

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-95c716eaf5492d2f1b15

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

end: 1500
end exclusive: true
exact text: is indicated
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1488

qualifier mentions

context exact
1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluoro
kind
age
polarity
not_inferred
span
end
1510
end exclusive
true
exact text
adults
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1504
context exact
1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine
kind
biomarker
polarity
not_inferred
span
end
1498
end exclusive
true
exact text
Metastatic Gastric Cancer Ogivri is indicat
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1455
context exact
abine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received
kind
biomarker
polarity
not_inferred
span
end
1657
end exclusive
true
exact text
HER2-overexpressing metastatic gastric or ga
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1613
context exact
on adenocarcinoma who have not received prior treatment for metastatic disease.
kind
biomarker
polarity
not_inferred
span
end
1756
end exclusive
true
exact text
metastatic disease
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1738
context exact
1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine o
kind
stage_or_setting
polarity
not_inferred
span
end
1500
end exclusive
true
exact text
Metastatic Gastric Cancer Ogivri is indicated
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1455
context exact
cil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for
kind
stage_or_setting
polarity
not_inferred
span
end
1678
end exclusive
true
exact text
metastatic gastric or gastroesophageal juncti
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1633
context exact
on adenocarcinoma who have not received prior treatment for metastatic disease.
kind
stage_or_setting
polarity
not_inferred
span
end
1756
end exclusive
true
exact text
metastatic disease
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1738
context exact
troesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1756
end exclusive
true
exact text
prior treatment for metastatic disease
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1718
context exact
.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic di
kind
regimen
polarity
not_inferred
span
end
1691
end exclusive
true
exact text
in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarci
label id
ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start
1512

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1757
end exclusive: true
exact text: 1.3 Metastatic Gastric Cancer Ogivri is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1451

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · unclassified context

application numbers

BLA761074

brand names

OGIVRI

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1898
end exclusive: true
exact text: or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] .
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1558

current approval status

not_reconciled

duplicate text group

dup-7cfdbb696950f9e4cd35

extraction review status

automated_candidate_pending_source_review

generic names

TRASTUZUMAB-DKST

ind-span-21ca8d9df8758ca2e8bc

label id

ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1898
end exclusive: true
exact text: Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] .
label id: ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bcea017c6e84c1f73ad4427cb05507513d2a8dab6c387171ee0754a49714a0a5
start: 1758

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f%22

spl effective date

2026-06-26

spl set id

b6465b44-a6dd-f99c-d009-6851cf05169c

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice